STUDY OF SERUM ADIPONECTIN AND HIGH SENSITIVITY C-REACTIVE PROTEIN IN DIABETIC PATIENTS
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i7.24252Keywords:
Adiponectin, High sensitivity C-reactive protein, Diabetes mellitus, Cardiovascular diseaseAbstract
Objectives: Adiponectin, a major cytokine from adipose tissue, and high sensitivity C-reactive protein (hs-CRP), well-established markers of inflammation are known to be associated with increased risk of cardiovascular disorders (CVD). Therefore the objective of our study was to evaluate the levels of these parameters and determine their correlation with glycemia to assess the cardiovascular risks in the patients with Type 2 diabetes mellitus.
Methods: This study was conducted in the Department of Biochemistry, Santosh Medical College, Ghaziabad, with 25 Type 2 diabetic patients and 25 age and sex-matched controls. Ethical clearance from the institution and informed consent from the patients were taken before the study. Adiponectin was analyzed by enzyme-linked immunoadsorbent assay, and blood sugar and CRP were estimated by the kit based method.
Results: Fasting blood sugar (FBS, 158.2±37.2) and hs-CRP (3.97±1.54) were significantly high, adiponectin was significantly low in the patients with diabetes compared to controls (80.52±9.72, 1.27±0.75, and 10.78±1.69, respectively, p<0.05). Adiponectin showed a negative correlation with FBS (r=−0.427) and hs-CRP (r=−0.336), but the correlation was significant only in case of FBS (p<0.05). hs-CRP positively correlated with FBS (r=0.568) and was statistically significant.
Conclusion: The results of our study further support the role of adiponectin and hs-CRP as a predictive biomarker of CVD risks in the patients suffering from Type 2 diabetes.
Downloads
References
Tripathi GK, Sharm R, Verma, Sharma P, Kumar P. Biomarkers in serum, uric acid as a risk factor for Type 2 diabetes associated with hypertension. Asian J Pharm Clin Res 2016;9:216-8.
Sharma R, Sharma P, Pradeep K, Tripathi GK. A correlation between Glycosylated Hemoglobin and Lipid profile in Type-2 Diabetes mellitus with and without complications. Int J Contemp Med 2015;3:120-5.
Dongway AC, Faggad AS, Zaki HY, Abdalla BE. C-reactive protein is associated with low-density lipoprotein cholesterol and obesity in type 2 diabetic sudanese. Diabetes Metab Syndr Obes 2015;8:427-35.
Sharma P, Kumar P, Sharma R, Prakash SW. Assessment of cardiometabolic risk factors among local population of NCR. Asian J Pharm Clin Res 2017;10:211-3.
Shivashankar M, Mani D. A brief overview of diabetes. Int J Pharm Pharm Sci 2011;3 suppl 4:22-7.
Brunzell JD, Davidson M, Furberg CD. Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008;31:811-22.
Kumpatla S, Karuppiah K, Immaneni S, Muthukumaran P, Krishnan J, Narayanamoorthy SK, et al. Comparison of plasma adiponectin and certain inflammatory markers in angiographically proven coronary artery disease patients with and without diabetes-A study from India. Indian J Med Res 2014;139:841-50.
Andayani T, Ibrahim MI, Asdie AH. The association of diabetes related factor and quality of life in Type 2 diabetes mellitus. Int J Pharm Pharm Sci 2010;2:130-45.
Saleh DK, Koosha P, Sadeghi M, Sarrafzadegan N, Afshar RK, Boshtam M, et al. Predictive role of adiponectin and high-sensitivity C-reactive protein for prediction of cardiovascular event in an Iranian cohort study: The Isfahan Cohort Study. Arya Atheroscler 2016;12:132 7.
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784-92.
Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85-9.
Pfutzner A, Forst T. High-sensitivity C- reactive protein as cardiovascular risk marker in patients with Diabetes Mellitus. Diabetes Technol Ther 2006;8:28-36.
Rakatzi I, Mueller H, Ritzeler O, Tennagels N, Eckel J. Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1. Diabetologia 2004;47:249-58.
Shreshtha S, Sharma P, Kumar P, Gupta G. Adiponectin: A review on physiological roles and associated disorders. Asian J Pharm Clin Res 2017;10:32-7.
Hardie DG. Mini review: The AMP-activated protein kinase cascade: The key sensor of cellular energy status. Endocrinology 2003;144:5179 83.
Lee S, Kwak SB. Role of adiponectin in metabolic and cardiovascular disease. J Exe Rehabil 2014;10:54-9.
Schmidt MI, Duncan BB. Diabesity: An inflammatory metabolic condition. Clin Chem Lab Med 2003;41:1120-30.
Qiao L, Lee B, Kinney B, Yoo HS, Shao J. Energy intake and adiponectin gene expression. Am J Physiol Endocrinol Metab 2011;300:E809-16.
Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in Type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.
Mohan V, Deepa R, Pradeepa R, Vimaleswaran KS, Mohan A, Velmurugan K et al. Association of low adiponectin levels with the metabolic syndrome - the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism 2005;54:476-81.
Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599-610.
Bahceci M, Tuzcu A, Ogun C, Canoruc N, Iltimur K, Aslan C. Is serum C-reactive protein concentration correlated with HbA1c and insulin resistance in Type 2 diabetic men with or without coronary heart disease? J Endocrinol Invest 2005;28:145-50.
Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD et al. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res 2000;1:81-8.
Festa A, Agostino RD, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The insulin resistance atherosclerosis study (IRAS). Circulation 2000;102:42-7.
Obot SA, Usoro CA, Anyanwu AC, Egbe ER, Ekott JU, Usoro AJ. Adiponectin and cardiovascular risk factors in relation with glycemic control in type 2 diabetics. Int J Res Med Sci 2013;1:563-70.
Ljubic S, Boras J, Jazbec A, Lovrencic MV, Vidjak V, Erzen DJ et al. Adiponectin has different mechanisms in Type 1 and Type 2 diabetes with C-peptide link. Clin Invest Med 2009;32:E271-9.
Streja D, Cressey P, Rabkin SW. Associations between inflammatory markers, traditional risk factors, and complications in patients with Type 2 diabetes mellitus. J Diabetes Complications 2003;17:120-7.
Wu T, Dorn JP, Donahue RP, Sempos CT, Trevisan M. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: The third national health and nutrition examination survey. Am J Epidemiol 2000;155:65-71.
Venkatesh B, Hickman I, Nisbet J, Cohen J, Prins J. Changes in serum adiponectin concentrations in critical illness: A preliminary investigation. Crit Care 2009;13:R105.
Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671-4.
Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003;52:942-7.
Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y et al. Inflammatory markers, adiponectin, and risk of Type 2 diabetes in the Pima Indian. Diabetes Care 2003;26:1745-51.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
